The effect of mast cell stabilizers on non-alcoholic fatty liver

Effect of mast cell stabilizers on elastographic findings of patients with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220104053626N6

Enrollment

Registered

2023-10-19

Start date

2023-11-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: In addition to their usual medications, Ketotifen 1mg tablets ( manufactured by Alhavi pharmaceutical company) will receive 2 times a day for 6 months . Interventio

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Age 18 to 59 years Willingness to participate in the study No history of alcohol consumption Do not take drugs with liver toxicity

Exclusion criteria

Exclusion criteria: Having liver disease with specific etiologies such as viral hepatitis Alcohol consumption Pregnancy and lactation Take other drugs anti histamine or anti cholinergic Cirrhosis of the liver Uncontrolled diabetes

Design outcomes

Primary

Measure	Time frame
Hepatic steatosis elastographic index in patients with non-alcoholic fatty liver disease. Timepoint: Before and after the intervention. Method of measurement: CAP index in liver elastography.;Hepatic fibrosis elastographic index in patients with non-alcoholic fatty liver disease. Timepoint: Before and after the intervention. Method of measurement: LSM index in liver elastography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasood Faghih Dinevari

Tabriz University of Medical Sciences

dinvarim@tbzmed.ac.ir+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026